The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage
- PMID: 23933235
- DOI: 10.1016/j.jconrel.2013.07.026
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage
Abstract
Despite the clinical introduction of an increasing number of polyethylene glycol (PEG)-conjugated substances, PEG has been named as the cause of an unexpected immunogenic response known as the "accelerated blood clearance (ABC) phenomenon." This phenomenon has been extensively observed during the repeated administration of PEG-conjugated substances and PEGylated nanocarriers including PEGylated liposomes, PEGylated nanoparticles, PEGylated micelles, etc., resulting in the increased clearance and reduced efficacy of PEG-conjugated substances/PEGylated nanocarriers. In this review, therefore, we focused on the possible mechanisms underlying the induction of such a phenomenon and emphasized the factors affecting its magnitude. In addition, the clinical implications of the ABC phenomenon on the therapeutic efficacy of PEG-conjugated substances/PEGylated nanocarriers, along with the new approaches that can be applied to manage and/or abrogate the induction of the ABC phenomenon, are also discussed.
Keywords: Accelerated blood clearance (ABC) phenomenon; Anti-PEG IgM; Polyethylene glycol(PEG); Repeated administration; Splenic B cells.
© 2013.
Similar articles
-
A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.Eur J Pharm Biopharm. 2018 Jun;127:142-149. doi: 10.1016/j.ejpb.2018.02.019. Epub 2018 Feb 17. Eur J Pharm Biopharm. 2018. PMID: 29462689
-
Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.Int J Pharm. 2013 Nov 1;456(1):235-42. doi: 10.1016/j.ijpharm.2013.07.059. Epub 2013 Aug 5. Int J Pharm. 2013. PMID: 23928149
-
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.Int J Pharm. 2008 Apr 16;354(1-2):56-62. doi: 10.1016/j.ijpharm.2007.11.005. Epub 2007 Nov 9. Int J Pharm. 2008. PMID: 18083313 Review.
-
[Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].Yao Xue Xue Bao. 2010 Jun;45(6):677-83. Yao Xue Xue Bao. 2010. PMID: 20939173 Review. Chinese.
-
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.Immunobiology. 2013 May;218(5):725-32. doi: 10.1016/j.imbio.2012.08.274. Epub 2012 Aug 23. Immunobiology. 2013. PMID: 22995937
Cited by
-
Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.J Control Release. 2016 Aug 10;235:306-318. doi: 10.1016/j.jconrel.2016.06.004. Epub 2016 Jun 4. J Control Release. 2016. PMID: 27266365 Free PMC article.
-
Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers.Asian J Pharm Sci. 2024 Feb;19(1):100883. doi: 10.1016/j.ajps.2023.100883. Epub 2023 Dec 29. Asian J Pharm Sci. 2024. PMID: 38357524 Free PMC article. Review.
-
Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy.Adv Sci (Weinh). 2021 Mar 1;8(8):2003679. doi: 10.1002/advs.202003679. eCollection 2021 Apr. Adv Sci (Weinh). 2021. PMID: 33898179 Free PMC article.
-
Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications.Polymers (Basel). 2022 Feb 9;14(4):658. doi: 10.3390/polym14040658. Polymers (Basel). 2022. PMID: 35215570 Free PMC article. Review.
-
The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.Blood Adv. 2023 Feb 28;7(4):620-629. doi: 10.1182/bloodadvances.2022007529. Blood Adv. 2023. PMID: 35858373 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
